Mechanism of Xinmaitong Tablets against Resistant Hypertension Based on Untargeted Proteomic Analysis

doi:10.19803/j.1672-8629.20240474

Abstract

Abstract: Objective To explore the potential mechanism by which the active ingredients of Xinmaitong tablets combat resistant hypertension using untargeted proteomic analysis methods. Methods Clinical samples were collected from patients with resistant hypertension (RH) and controlled hypertension (CH) respectively. Using untargeted proteomic technology, differential proteins in plasma from the two groups of patients were characterized. The active ingredients and targets of Xinmaitong tablets were retrieved from the TCMSP and PharmMapper databases. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using the Metascape database. Intersection targets of the drug with differentially expressed proteins in RH patients were identified, and molecular docking validation was conducted using the MOE software. Results A total of 162 active ingredients from Xinmaitong tablets were obtained, and 2 intersection targets between the drug and differentially expressed proteins in resistant hypertension were identified. The key active ingredients of Xinmaitong tablets for treating hypertension were baicalin, spinasterol, luteolin, kaempferol, quercetin, stigmasterol, and β-sitosterol while the core targets were Peptidyl-prolyl cis-trans isomerase A (PPIA) and heat shock protein HSP 90-alpha (HSP90AA1). GO and KEGG enrichment analysis involved the top 20 signaling pathways, including platelet degranulation, neutrophil degranulation, and inflammatory response signaling pathways. Molecular docking showed good binding activity between the key active ingredients and the core targets. Conclusion Xinmaitong tablets may exert their therapeutic effect against resistant hypertension by acting on PPIA through baicalin.

Key words: Xinmaitong Tablets, Baicalin, Spinasterol, Resistant Hypertension, Untargeted Proteomic Analysis, Molecular Docking, Mechanism, Therapeutic Effect

CLC Number:

R972

DU Jianmin, ZHANG Chenning, ZHANG Xinghai, ZHANG Wenyu, ZHAO Hengli, WEN Qing. Mechanism of Xinmaitong Tablets against Resistant Hypertension Based on Untargeted Proteomic Analysis[J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1270-1275.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240474

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I11/1270

References

[1] LAMIRAULT G, ARTIFONI M, DANIEL M, et al.Resistant Hypertension: Novel Insights[J]. Curr Hypertens Rev, 2020, 16(1): 61-72.
[2] Writing Group of Chinese Guidelines for the Management of Hypertension Chinese Hypertension League Chinese. Chinese Guidelines for the Prevention and Treatment of Hypertension(2018 revision)[J]. Chinese Journal of Cardiovascular Medicine(中国心血管杂志), 2019, 24(1): 24-56.
[3] AGU PC, AFIUKWA CA, ORJI OU, et al.Molecular Docking as a Tool for the Discovery of Molecular Targetsof Nutraceuticals in Diseases Management[J]. Sci Rep, 2023, 13(1): 13398.
[4] WISNIEWSKI JR, ZOUGMAN A, NAGARAJ N, et al.Universal Sample Preparation Method for Proteome Analysis[J]. Nat Methods, 2009, 6(5): 359-362.
[5] BOWLER-BARNETT EH, FAN J, LUO J, et al.UniProt and Mass Spectrometry-Based Proteomics-a 2-Way Working Relationship[J]. Mol Cell Proteomics, 2023, 22(8): 100591.
[6] ZHU Y, XIONG H, LIU S, et al.Combining MOE Bioinformatics Analysis and In Vitro Pseudovirus Neutralization Assays to Predict the Neutralizing Ability of CV30 Monoclonal Antibody on SARS-CoV-2 Variants[J]. Viruses, 2023, 15(7): 1565.
[7] DYBIEC J, KRZEMIŃSKA J, RADZIOCH E, et al. Advances in the Pathogenesis and Treatment of Resistant Hypertension[J]. Int J Mol Sci, 2023, 24(16): 12911.
[8] LEOPOLD JA, INGELFINGER JR.Aldosterone and Treatment-Resistant Hypertension[J]. N Engl J Med, 2023, 388(5): 464-467.
[9] LAUDER L, MAHFOUD F, BÖHM M. Management of Resistant Hypertension[J]. Annu Rev Med, 2024, 75: 443-457.
[10] XIANG WL, HENG XY.Clinical Efficacy and Quality of Life Evaluation of Cardiovascular Capsule in the Treatment of Ischemic Stroke[J]. Chinese Journal Medical Guide(中国医药导刊), 2015, 17(8): 812-814.
[11] CHENG Y, YAN M, HE S, et al.Baicalin Alleviates Angiotensin II-Induced Cardiomyocyte Apoptosis and Autophagy and Modulates the AMPK/mTOR Pathway[J]. J Cell Mol Med, 2024, 28(9): e18321.
[12] HE L M, WANG H, ZHAO HY, et al.Effects of Baicalin on Blood Pressure and Inhibition of Left Ventricular Remodeling in Renal Hypertensive Rats[J]. Chinese Journal of Arteriosclerosis(中国动脉硬化杂志), 2017, 25(7): 693-700.
[13] DING L, JIA C, ZHANG Y, et al.Baicalin Relaxes Vascular Smooth Muscle and Lowers blood Pressure in Spontaneously Hypertensive Rats[J]. Biomed Pharmacother, 2019, 111: 325-330.
[14] LIU H, CHENG Y, CHU J, et al.Baicalin Attenuates Angiotensin II-Induced Blood Pressure Elevation and Modulates MLCK/p-MLC Signaling Pathway[J]. Biomed Pharmacother, 2021, 143: 112124.
[15] HADPECH S, THONGBOONKERD V.Current Update on Theranostic Roles of Cyclophilin a in Kidney Diseases[J]. Theranostics, 2022, 12(9): 4067-4080.
[16] WU Y, MA Z, ZHANG Y, et al. Cyclophilin a Regulates the Apoptosis of A549 Cells by Stabilizing Twist1 Protein[J]. J Cell Sci, 2022, 135(2): jcs259018.
[17] GKALIAGKOUSI E, PASSACQUALE G, DOUMA S, et al.Platelet Activation in Essential Hypertension: Implications for Antiplatelet Treatment[J]. Am J Hypertens, 2010, 23(3): 229-236.
[18] VAN BRUGGEN S, JARROT PA, THOMAS E, et al.NLRP3 is Essential for Neutrophil Polarization and Chemotaxis in Response to Leukotriene B4 Gradient[J]. Proc Natl Acad Sci USA, 2023, 120(35): e2303814120.